Expiration date: 07/2025

The composition and form of issue:

1 tablet contains losartan potassium 12.5 or 50 mg, in a contour acheikova packing 21 or 14 PCs., in box 2, and 1 box respectively.

Pharmacological action:

Blocks the angiotensin II receptor (type AT1) reduces peripheral vascular resistance, decreases afterload, reduces systemic blood pressure and the pressure in the pulmonary circulation.

Pharmacokinetics:

It is well absorbed. Is distributed relatively evenly. Metabolised education active derivative.

Description pharmacological action:

Maximum antihypertensive effect is achieved after 3-6 weeks of treatment.

Indications:

Hypertension, heart failure (including when the treatment of ACE inhibitors are more is not suitable for the patient.

Contraindications:

Hypersensitivity, children's age.

Application of pregnancy and breast-feeding:

If pregnancy reception immediately cease (can cause developmental defects or death of the fetus, especially in II-III trimester). Nursing mothers should stop breast-feeding.

Side effects:

Dizziness, hypotension (dose-dependent), hyperkalemia (1.5% of patients).

Drug interactions:

Compatible with other antihypertensive agents. On a background of diuretics (large doses) increases the risk of excessive hypotension in patients with dehydration.

Method of application and dose:

Inside, regardless of meals, once. Typically 50 mg/day. In some cases, to maximize the effect, increase the dose to 100mg. patients with dehydration, the initial dose may be 25 mg/day. For patients with heart failure the initial dose may be 12.5 mg 1 time per day.

Overdose:

The most likely manifestation is hypotension and tachycardia (possible vagal bradycardia). Treatment is symptomatic — no Cozaar nor its active metabolite are excreted by hemodialysis.

Precautions:

Patients with liver diseases in history it is necessary to appoint smaller doses (plasma concentration increases significantly when violations of its functions, especially with cirrhosis).